摘要
目的:研究骨髓增生异常综合征和急性髓系白血病治疗中地西他滨单药及联合半程和全程HA方案的效果。方法:采用回顾性分析方法,选择2016年6月至2019年6月入院的80例骨髓增生异常综合征与急性髓系白血病患者,参考不同治疗方式分为研究组(40例)与对照组(40例),研究组选用地西他滨联合全程HA方案治疗,对照组选用地西他滨联合半程HA方案治疗;比较两组治疗后血小板、中性粒细胞减少持续时间、缓解率、总反应率及毒副反应发生率。结果:研究组治疗后血小板、中性粒细胞减少持续时间与缓解率、总反应率及毒副反应发生率依次为(10.18±0.98)d、(11.57±1.34)d、70.00%、82.50%、7.50%,对照组治疗后血小板、中性粒细胞减少持续时间与缓解率、总反应率及毒副反应发生率依次为(16.45±1.46)d、(18.03±1.92)d、30.00%、60.00%、25.00%。研究组较对照组治疗后血小板、中性粒细胞减少持续时间更短,缓解率及总反应率更高,毒副反应发生率更低(P<0.05)。结论:地西他滨联合全程HA方案治疗骨髓增生异常综合征和急性髓系白血病的效果优于地西他滨联合半程HA方案,且毒副反应少。
Objective: To study the effect of decitabine monotherapy and combined half-course and full-course HA regimen in the treatment of myelodysplastic syndrome and acute myeloid leukemia. Methods: Using a retrospective analysis method, 80 patients with myelodysplastic syndrome and acute myeloid leukemia admitted from June 2016 to June 2019 were selected. According to different treatment methods, they were divided into a research group and a control group(each 40 cases), the study group was treated with decitabine combined with full-course HA regimen, and the control group was treated with decitabine combined with half-course HA regimen;the duration and response rate of platelet and neutrophil decrease after treatment were compared. Results: After treatment, the duration of platelet and neutropenia and remission rate, total response rate and incidence of toxic and side effects were(10.18 ±0.98) d,(11.57±1.34) d, 70.00 %, 82.50 % 7.50 %, the control group’s platelet, neutropenia duration and remission rate, total response rate and incidence of toxic and side effects were(16.45±1.46) d,(18.03±1.92) d, 30.00 %, 60.00 %, 25.00 %. Compared with the control group,the study group had shorter duration of platelet and neutropenia, higher remission rate and total response rate, and lower incidence of toxic and side effects(P<0.05). Conclusion: Decitabine combined with full-course HA regimen was better than decitabine combined with half-course HA regimen in treating myelodysplastic syndrome and acute myeloid leukemia, and it had fewer toxic and side effects.
作者
王晗晗
许力
武琳琳
江慧敏
夏亮
陶千山
张家奎
WANG Han-han;XU Li;WU Lin-lin;JIANG Hui-min;XIA Liang;TAO Qian-shan;ZHANG Jia-kui(Department of Hematology,Anhui NO.2 Provincial People's Hospital(Clinical College of Anhui Medical University),Hefei,Anhui,230041,China;Department of Hematology,the Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui,230601,China)
出处
《现代生物医学进展》
CAS
2021年第1期150-153,共4页
Progress in Modern Biomedicine
基金
安徽省高校自然科学研究重点项目(KJ2019A1107)。
